Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03758287
Recruitment Status : Recruiting
First Posted : November 29, 2018
Last Update Posted : September 18, 2020
Sponsor:
Information provided by (Responsible Party):
Sunshine Lake Pharma Co., Ltd.

Brief Summary:
This is a phase Ib, multi-center, open label study evaluating the safety and efficacy of CT053PTSA in combination with gefitinib in patients with EGFR mutation, T790M negative NSCLC who have progressed after EGFR TKI treatment.

Condition or disease Intervention/treatment Phase
Non-small Cell Lung Cancer Drug: CT053PTSA Drug: Gefitinib Phase 1 Phase 2

Detailed Description:

This study is being carried out in two parts, part 1 and part 2.

Part 1: This is the dose-escalation part. The primary purpose of the part 1 portion is to determine the dose limiting toxicity (DLT) and maximum tolerated dose (MTD), and recommend the appropriate doses of CT053PTSA in combination with gefitinib for further studies.

Part 2: This is the expansion part. The part 2 portion of this study will continue to evaluate the safety and efficacy of the combination of CT053PTSA and gefitinib , at the appropriate doses recommended in Part 1, in patients with EGFR mutation, T790M negative NSCLC.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 158 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase Ib, Multi-center, Open Label Study of Ningetinib (CT053PTSA) in Combination With Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative Who Have Progressed After EGFR TKI Therapy
Actual Study Start Date : November 2016
Estimated Primary Completion Date : August 17, 2021
Estimated Study Completion Date : November 17, 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Gefitinib

Arm Intervention/treatment
Experimental: CT053PTSA +Gefitinib

Patients will receive CT053PTSA and gefitinib over a 28-day cycle until progressive disease, intolerable toxicity or subject's withdrawal from treatment.

CT053PTSA will be administered daily, at a dose of 30 mg/40mg/60mg orally .

Gefitinib will be administered daily, at a dose of 250 mg orally .

Drug: CT053PTSA
Other Name: Ningetinib

Drug: Gefitinib
Other Name: Iressa




Primary Outcome Measures :
  1. Part 1(dose-escalation part): Maximum Tolerated Dose (MTD) [ Time Frame: Cycle 1 Day 1 to Cycle 1 Day 28 ]
    The maximum tolerated dose (MTD) of the CT053PTSA and gefitinib combination will be determined according to incidence of dose-limiting toxicity (DLT) assessed by NCI CTCAE v4.03

  2. Part 2(expansion part): Overall Response Rate [ Time Frame: up to approximately 36 months ]
    Overall response rate (ORR), defined as a partial response (PR) or complete response (CR) occurring at any point post-treatment according to Response Evaluation Criteria in Solid Tumors as assessed by RECIST v1.1


Secondary Outcome Measures :
  1. Number of patients with adverse events (AEs) as a measure of safety and tolerability [ Time Frame: up to approximately 36 months ]
    Safety and tolerability will be assessed through AEs, via monitoring changes in physical examination, clinical laboratory parameters, vital signs and ECGs

  2. Disease Control Rate (DCR) [ Time Frame: up to approximately 36 months ]
    DCR, proportion of patients with best overall response of CR, PR or SD

  3. Progression-free Survival (PFS) [ Time Frame: up to approximately 36 months ]
    PFS, defined as time from date of treatment to disease progression or death due to any cause

  4. Duration of Response (DOR) [ Time Frame: up to approximately 36 months ]
    DOR, defined as time from the first documented CR or PR to first documented progression or death due to any cause

  5. Overall Survival (OS) [ Time Frame: up to approximately 60 months ]
    OS, defined as time from date of treatment to death due to any cause

  6. Maximum observed plasma concentration (Cmax) [ Time Frame: Cycle 1 Day1 and Day 28 ]
    to assess the pharmacokinetic profile

  7. Time of maximum observed plasma concentration (Tmax) [ Time Frame: Cycle 1 Day1 and Day 28 ]
    to assess the pharmacokinetic profile

  8. Area under the plasma concentration time curve (AUC) [ Time Frame: Cycle 1 Day1 and Day 28 ]
    to assess the pharmacokinetic profile



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically confirmed Stage IIIB or IV NSCLC
  • Resistance to EGFR TKI (1st, 2nd or 3rd generation)
  • Histological or cytological evidence of EGFR mutation and T790M negative after progression on last EGFR TKI therapy
  • c-Met GCN ≥ 6 or cluster amplification is required if participant is resistant to1st or 2nd generation EGFR-TKI ;c-MET GCN statue is not required, If participant is resistant to3rd generation EGFR-TKI (osimertinib);
  • Measurable disease according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
  • Toxicity recovered to NCI CTCAE v.4.03 Grade ≤1 from previous treatments (except alopecia)
  • ECOG performance status (PS) 0 or 1
  • Life expectancy of ≥ 12 weeks
  • Adequate organ function

Exclusion Criteria:

  • Prior treatments

    • Chemotherapy, targeted therapy (except EGFR TKI), immunotherapy, radiotherapy, or major surgery within 4 weeks prior to study treatment
    • Nitrosourea and mitomycin chemotherapy within 6 weeks prior to study treatment
    • EGFR TKI treatment within 2 weeks prior to study treatment
    • Had received live vaccine within 4 weeks prior to study treatment
    • Had received any investigational agent from other clinical study within 4 weeks prior to study treatment or are currently participating in other clinical trials
    • Previous treatment with any other c-MET inhibitor or Axl inhibitor (eg, crizotinib, cabozantinib, volitinib, INC280)
  • Symptomatic, untreated or unstable central nervous system metastases
  • Spinal cord compression, carcinomatous meningitis or leptomeningeal diseaseonly (patient are only permitted if treated, asymptomatic and stable for at least 4 weeks prior to start of study treatment)
  • Interstitial pneumonia or radiation pneumonitis
  • Uncontrolled hypertension that require more than two anti-hypertensive agents to control, or systolic blood pressure (BP) >140mmHg or diastolic BP >90 mmHg before the first administration (BP is the mean blood pressure of two measures that 1 hours interval or above)
  • Doppler ultrasound evaluation:Left ventricular ejection fraction < 50%
  • Grade ≥ 2 of arrhythmia (assessed by NCI CTCAE 4.03), or symptomatic bradycardia, or male with QTCF > 450 ms or female with QTCF > 470 ms, or patients with a history of torsion or congenital QT prolonged syndrome long QT syndrome
  • Certain factors that would preclude adequate absorption of CT053PTSA and gefitinib (eg. unable to swallow, chronic diarrhea, intestinal obstruction)
  • Significant hemoptysis within 2 months prior to enrollment, or a daily hemoptysis volume is 2.5 ml or above
  • Patients with evidence of bleeding tendency, including the following cases: gastrointestinal bleeding, hemorrhagic gastric ulcer, fecal occult blood ++ and above; or melena or hematemesis within 2 months; or visceral bleeding that may occur considered by investigator
  • History of immunodeficiency, or other acquired or congenital immunodeficiency, or history of organ transplantation
  • Any disease of the following bellowed within 12 months prior to administration: Myocardial infarction, severe angina, or unstable angina, coronary or peripheral artery bypass graft, congestive heart failure, or cerebrovascular events (including transient ischemic attack)
  • Pulmonary embolism within 6 months prior to administration
  • Active infection of hepatitis B, or infection of HIV
  • Other malignancies within 5 years prior to enrollment, with the exception of carcinoma in situ of the cervix, basal or squamous cell skin cancer
  • History of thyroid dysfunction, and the thyroid function cannot be maintained at the normal range with drugs.
  • Serious electrolyte imbalance in the investigator's judgment
  • Pregnant or lactating woman
  • Any other reason the investigator considers the patient is not suitable to participate in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03758287


Contacts
Layout table for location contacts
Contact: Li Zhang, MD (086)020-87343458 zhangli@sysucc.org.cn

Locations
Layout table for location information
China, Guangdong
Sun Yat-sen University Cancer Center Recruiting
Guangzhou, Guangdong, China, 510060
Contact: Li Zhang, MD         
Principal Investigator: Li Zhang, MD         
Sponsors and Collaborators
Sunshine Lake Pharma Co., Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Li Zhang, MD Sun Yat-sen University
Layout table for additonal information
Responsible Party: Sunshine Lake Pharma Co., Ltd.
ClinicalTrials.gov Identifier: NCT03758287    
Other Study ID Numbers: PCD-DCT053-16-001
First Posted: November 29, 2018    Key Record Dates
Last Update Posted: September 18, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Gefitinib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action